Cipla advances on entering into partnership with Eli Lilly

08 Jun 2018 Evaluate

Cipla is currently trading at Rs. 558.05, up by 17.80 points or 3.29% from its previous closing of Rs. 540.25 on the BSE.

The scrip opened at Rs. 540.10 and has touched a high and low of Rs. 560.45 and Rs. 539.50 respectively. So far 147808 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 663.00 on 07-Nov-2017 and a 52 week low of Rs. 508.10 on 22-May-2018.

Last one week high and low of the scrip stood at Rs. 560.45 and Rs. 517.80 respectively. The current market cap of the company is Rs. 44926.83 crore.

The promoters holding in the company stood at 37.21%, while Institutions and Non-Institutions held 38.10% and 24.69% respectively.

Cipla has entered into partnership with Eli Lilly and Company (India), a 100% subsidiary of Eli Lilly and Company, a global multinational pharmaceutical leader. Under this agreement, Lilly’s Basaglar that is manufactured by Lilly will be marketed and distributed in India by Cipla. Basaglar is a once-daily insulin glargine therapy for the treatment of patients with type 1 & 2 diabetes above two years of age.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.


Cipla Share Price

1457.60 -8.55 (-0.58%)
12-Jan-2026 11:13 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.85
Dr. Reddys Lab 1204.65
Cipla 1457.60
Zydus Lifesciences 890.15
Lupin 2166.90
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×